Citius Pharmaceuticals, Inc. has reported a remarkable 120% increase in unit sales of its oncology drug LYMPHIR during the fiscal fourth quarter ended September 30, 2026. This surge in sales reflects a growing institutional demand for the drug, which is a targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). The announcement is significant for Citius as it showcases the effectiveness of its commercial strategy and positions the company favorably within the pharmaceutical preparations sector.
On October 26, 2026, Citius's wholly-owned subsidiary, Citius Oncology, Inc., shared preliminary, unaudited sales figures in a press release. The increase in LYMPHIR sales comes as the company expands its commercial team, achieving nationwide coverage in August. Leonard Mazur, Chairman and CEO of Citius Oncology, expressed optimism about the future, stating, “The fiscal fourth quarter showed continued institutional demand for LYMPHIR. Unit sales to wholesalers more than doubled as our expanded commercial team reached nationwide coverage in August.”
Background
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative critical care products. The company operates under the SIC classification of 2834, which pertains to pharmaceutical preparations. Citius is listed on the Nasdaq under the ticker symbol CTXR. Recently, the firm has been active in filing reports with the SEC, including an 8-K on October 26, 2026, detailing its financial performance.
What the Filing Says
The SEC filing indicated that Citius Oncology reported 792 units sold to U.S. wholesalers for the fourth quarter, up from 360 units in the previous quarter. Additionally, 950 LYMPHIR vials were ordered by prescribing centers during this period, compared to 926 in the third quarter. The company also noted that 54 institutions have ordered LYMPHIR, an increase from 44 reported earlier in August.
Impact
This surge in sales is likely to have a positive impact on Citius Pharmaceuticals' financial condition, potentially enhancing investor confidence and market perception. The growth in LYMPHIR sales may also influence competitors in the oncology sector, as it highlights the demand for effective treatments in a competitive landscape. The company’s strategy to increase institutional adoption of LYMPHIR could set a precedent for similar firms in the industry.
What's Next
Citius Pharmaceuticals is expected to report complete fiscal fourth quarter results and the full fiscal year 2026 results in December 2026, coinciding with the filing of its Annual Report on Form 10-K. This forthcoming report will provide a more comprehensive view of the company's financial health and operational performance.